Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the second quarter of 2025 and upped annual ...

Sales of Kisqali, which treats metastatic breast cancer, surged 64% globally on a constant currency basis in the three months ...

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Novartis AG stands third among the most undervalued ...

Jacob E. Berchuck, MD, highlights novel findings pointing to androgen receptor signaling and Wnt pathway activation as key ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate ...

Prostate cancer is the most common cancer in men, and the second leading cause of cancer-related death. ... One known as Pluvicto is a series of injections given every six weeks, ...